Clinical Report: Electrochemotherapy Applications in Pediatric Patients

Overview

This systematic review summarizes the current use of electrochemotherapy (ECT) in pediatric patients, highlighting its applications in refractory tumors and vascular anomalies. The review includes data from 15 studies involving 127 children, demonstrating ECT's feasibility, safety, and potential efficacy in this population.

Background

Electrochemotherapy combines chemotherapeutic agents with electroporation to enhance intracellular drug delivery, increasing cytotoxicity while limiting systemic exposure. Bleomycin is the most commonly used agent, with electroporation markedly enhancing its uptake. Although widely studied in adults for various tumors, ECT remains underused in pediatrics due to limited data and concerns about long-term effects. Emerging evidence suggests ECT may be a valuable option for refractory or inoperable pediatric tumors and vascular anomalies.

Data Highlights

Key Findings

• ECT enhances intracellular delivery of chemotherapeutic agents, primarily bleomycin, via reversible electroporation.
• ECT has been applied in pediatric patients for cutaneous tumors, vascular anomalies, and refractory lesions with promising safety and efficacy.
• Fifteen studies included 127 pediatric patients with a mean age of 8.5 years, treated across multiple European centers.
• Multidisciplinary teams including dermatologists, surgeons, and radiologists have contributed to pediatric ECT applications.
• ECT protocols and dosing vary, with bleomycin dosing inconsistently reported, emphasizing the need for standardized reporting.
• Long-term safety data in pediatric populations remain limited but initial reports suggest acceptable tolerability.

Clinical Implications

ECT represents a minimally invasive treatment option for pediatric patients with refractory tumors and vascular anomalies, potentially reducing the need for extensive surgery. Clinicians should consider multidisciplinary collaboration and standardized protocols to optimize outcomes. Further research is needed to establish long-term safety and efficacy in children.

Conclusion

Electrochemotherapy shows promise as a safe and effective treatment modality in pediatric oncology and vascular anomalies, warranting further investigation and standardized clinical application. Its integration into pediatric care may expand therapeutic options for challenging cases.

References

1. Mir et al. 1991 -- Electrochemotherapy: Basic principles and clinical applications
2. European Standard Operating Procedures of Electrochemotherapy (ESOPE) 2006 -- Standardization of ECT protocols
3. Campana et al. 2019 -- Electrochemotherapy in pediatric patients: A systematic review